Evidence map›Paper›PMID 42053700›Full record

ReviewMolecular neurobiology2026

Therapeutic Mechanisms of Stem Cell-Derived Exosomes for Neurological Disorders: An Overview.

Congying Lin, Lixin Qi, Xiuying Gao, Lei Hu, Bo Qian, Yixuan Deng, Chunting Zhou, Chenyi Wang, Guanhao Liu, Qiang Ding and 3 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Molecular neurobiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Congying LinDepartment of Neonatology, the Second School of Medicine, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.
Lixin QiThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Xiuying GaoThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Lei HuThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Bo QianThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Yixuan DengSchool of Ophthalmology & Optometry and Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Chunting ZhouThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Chenyi WangThe First School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Guanhao LiuThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Qiang DingThe Second School of Medicine, Wenzhou Medical University, Wenzhou, Zhejiang, China.
Zhenlang LinDepartment of Neonatology, the Second School of Medicine, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. linzhenlang@hotmail.com.
Xuwei ZhuDepartment of Orthopaedics (Division of Hand Surgery), the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, 109 Xueyuan West Road, Wenzhou, 325027, Zhejiang, China. drzhuxuwei@163.com.
Min ZhangDepartment of Neonatology, the Second School of Medicine, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China. zmzhangmin2018@163.com.

Funding

he Zhejiang Provincial Key Research and Development Program 2025C02081the China Postdoctoral Science Foundation 2025M783998the National Natural Science Foundation of China 82271747the National Natural Science Foundation of China 82505180Wenzhou Major Scientific and Technological Innovation Project ZY2023013
6 · The paper itself

Abstract

The current management of neurological disorders remains largely symptomatic. In recent years, stem cell-derived exosomes have emerged as a promising alternative therapeutic strategy. This narrative review synthesizes evidence from preclinical studies investigating the mechanisms and efficacy of exosome-based therapy for neurological conditions. The included studies encompass animal models and in vitro systems. Accumulating preclinical evidence consistently supports the therapeutic potential of stem cell-derived exosomes across several neurological disorders. In Alzheimer's disease models, stem cell-derived exosomes reduce β-amyloid plaque deposition and attenuate neuroinflammation. For Parkinson's disease, they exert neuroprotective effects on dopaminergic neurons. They also inhibit α-synuclein aggregation. In ischemic stroke and spinal cord injury, stem cell-derived exosomes promote functional recovery through multiple mechanisms. These include suppressing ferroptosis, promoting angiogenesis, and stimulating axonal regeneration. Improved delivery strategies, such as intranasal administration and hydrogel encapsulation, have further enhanced brain targeting and treatment durability. Despite these promising preclinical findings, several challenges remain. A primary issue is the lack of standardized preparation protocols. Significant uncertainties also exist regarding long-term safety. Furthermore, pathways for clinical translation are still unclear. Future research should prioritize elucidating the underlying mechanisms of exosome therapy. The refinement of targeted delivery systems is equally important. Finally, advancing rigorously designed clinical trials is crucial to facilitate the translation of these therapies into clinical practice.

Indexed as

ExosomesNervous System DiseasesStem CellsAnimalsHumansExosomesIschemic strokeNeurological disordersSpinal cord injuryStem cells

Identifiers

PMID42053700

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.